prostate cancer

New Products: Neuromodulation system for OAB targets tibial nerveOther products discussed in this roundup include a plasma vaporization device, a laser fiber safety device, and more.
Low concordance with NCCN surveillance guide seenConcordance with National Cancer Comprehensive Network recommendations about follow-up during active surveillance for low-risk prostate cancer is generally low across urology practices in Michigan, reported researchers from the Michigan Urological Surgery Improvement Collaborative at the AUA annual meeting in San Diego.
Adjuvant chemo well tolerated in high-risk PCa patientsA Veterans Administration Cooperative Study investigating chemotherapy after prostatectomy for high-risk prostate cancer was underpowered to show a statistically significant benefit of early adjuvant chemotherapy versus observation as the standard of care in the primary endpoint analysis of progression-free survival.
Basic Science Research: Trimodal therapy shows promise in oligometastatic PCaOther basic science research pearls include preliminary evidence from a porcine model suggesting botulinum toxin type A facilitates ureteral stone passage and the identification of two different microdeletions in the NELL1 gene on chromosome 11 in men with Peyronie's disease.
Outcomes Analysis: Decline observed in PSA-based screening for PCaStudies about ProPublica's Surgeon Scorecard, urology participation in accountable care organizations, and Twitter were among the take-home messages in outcomes analysis at the 2016 AUA annual meeting. The take-homes were presented by Christopher Saigal, MD, MPH, of the University of California, Los Angeles.
Long-term TRT use reduces risk of CV events, PCaThere is no excess risk of death, prostate cancer diagnosis, or cardiovascular events with long-term testosterone replacement therapy, Canadian researchers have found in a population-based matched cohort study.
Prostate Ca: PSA drop, active surveillance are key themesFusion biopsy, salvage versus adjuvant radiation therapy, and superextended versus extended pelvic lymph node dissection are also covered in the take home messages on prostate cancer from the 2016 AUA annual meeting.
Landmark prostate cancer screening trial criticizedThe authors of a recent NEJM letter question the validity of the controversial Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Active surveillance initiative raises adoption of strategyAn academic center/community practice collaboration increases use of surveillance among prostate cancer patients “through use of provider education and a standardized report card,” a study author said.
Assay predicts outcomes in men taking mCRPC agentExpression of androgen receptor splice variant 7 (AR-V7) in whole blood predicts worse cancer-related outcomes in patients with metastatic castration-resistant prostate cancer who are treated with abiraterone acetate (ZYTIGA).